BioMed X & Merck Advance Precision Oncology with New Research Breakthrough

The independent research organization BioMed X has finalized its oncology research initiative in collaboration with Merck, whose data has been obtained by Merck for additional development, possibly resulting in innovative therapeutic methods in precision oncology.

Initiated in August 2022, the partnership sought to decode the processes involved in the generation, spread, and influence of ecDNA in cancer cells through single-cell screening and spatial technologies. The initiative was directed by Dr. Alexandros Drainas, who won the BioMed X Innovation Boot Camp, and was guided by Dr. Sebastian M. Waszak, Assistant Professor at EPFL in Lausanne, Switzerland. Dr. Balca Mardin, Head of Target Discovery & Research at Merck, provided guidance for the industry.

The team's study discovered genes that could decrease ecDNA levels in cancer cells. Moreover, the team created sophisticated spatial technologies to investigate how the localization of ecDNA influences the adaptability of cancer cells. These results could provide hopeful approaches for addressing cancer diversity and decreasing the factors contributing to treatment resistance, which may enhance the effectiveness of current therapies.

Dr. Thomas Rückle, Senior Vice President of Research at the BioMed X Institute, said: “The knowledge gained from this project not only advances cancer research but also showcases the potential of ecDNA-targeted therapies. We look forward to continuing our successful partnership with Merck and our joint journey towards a deeper understanding of complex life-threatening diseases.”